RP-3 is under clinical development by Replimune and currently in Phase I for Lung Cancer.
Study breaks down Alzheimer’s treatment effects in clear terms
In the past two years, the Food and Drug Administration has approved two novel Alzheimer’s therapies, based on data from clinical trials showing that both